Tenax presented completed LEVEL analyses at ESC, highlighting a prespecified 26.3-meter subgroup benefit even though the 241-patient Phase 3 trial failed overall.

Bristol Myers reported sustained reductions in cardiac obstruction and symptom improvement through 252 weeks in the single-arm EXPLORER-LTE extension study of Camzyos.

Marriott’s August 29 redemption retires the 5.450% Series LL notes 17 days before maturity, with payment moving to the next business day because the redemption date falls on a Saturday.

Gabelli’s proposed GRIT ETF reached the effective date designated in its latest SEC amendment after a series of postponements stretching from April through August.

Starting Repatha before PCI lifted 12-month LDL goal attainment to 81.6% from 39.6%, but death or unplanned cardiovascular hospitalization was 14.6% versus 15.4%.

The U.S. Commerce Department amended a prior antidumping review of UAE welded steel pipe after a court ruling, raising Universal’s margin to 3.64% from 2.63%.

Vesalio said enVast-assisted thrombectomy reduced the trial’s CK-MB-based infarct-size endpoint by nearly 26% versus standard care in STEMI patients with large thrombus burden.

KEO Energy said its U.S. subsidiary signed the PetroUrdaneta operating framework with PDVSA, including service, payment administration and financing agreements that can provide up to $350 million for the Venezuelan joint venture.

Six-month TRANQUILITY data showed sustained hs-CRP reductions across monthly and quarterly pacibekitug regimens, supporting further Phase 3 cardiovascular evaluation.

The 948-patient ENRICH-AF trial found no significant reduction in stroke or systemic embolism with edoxaban, while major bleeding rose to 11.6% from 5.2%.